Literature DB >> 30635237

Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy.

Imran Siddiqui1, Karin Schaeuble1, Vijaykumar Chennupati1, Silvia A Fuertes Marraco1, Sandra Calderon-Copete2, Daniela Pais Ferreira1, Santiago J Carmona3, Leonardo Scarpellino4, David Gfeller3, Sylvain Pradervand2, Sanjiv A Luther4, Daniel E Speiser1, Werner Held5.   

Abstract

Checkpoint blockade mediates a proliferative response of tumor-infiltrating CD8+ T lymphocytes (TILs). The origin of this response has remained elusive because chronic activation promotes terminal differentiation or exhaustion of tumor-specific T cells. Here we identified a subset of tumor-reactive TILs bearing hallmarks of exhausted cells and central memory cells, including expression of the checkpoint protein PD-1 and the transcription factor Tcf1. Tcf1+PD-1+ TILs mediated the proliferative response to immunotherapy, generating both Tcf1+PD-1+ and differentiated Tcf1-PD-1+ cells. Ablation of Tcf1+PD-1+ TILs restricted responses to immunotherapy. Tcf1 was not required for the generation of Tcf1+PD-1+ TILs but was essential for the stem-like functions of these cells. Human TCF1+PD-1+ cells were detected among tumor-reactive CD8+ T cells in the blood of melanoma patients and among TILs of primary melanomas. Thus, immune checkpoint blockade relies not on reversal of T cell exhaustion programs, but on the proliferation of a stem-like TIL subset.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  T cell exhaustion; T cell factor 1; T cell reinvigoration; cancer immunotherapy; checkpoint blockade; memory-like T cells; stem-like T cells; therapeutic vaccination

Mesh:

Substances:

Year:  2019        PMID: 30635237     DOI: 10.1016/j.immuni.2018.12.021

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  332 in total

1.  SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery.

Authors:  Siwen Hu-Lieskovan; Srabani Bhaumik; Kavita Dhodapkar; Jean-Charles J B Grivel; Sumati Gupta; Brent A Hanks; Sylvia Janetzki; Thomas O Kleen; Yoshinobu Koguchi; Amanda W Lund; Cristina Maccalli; Yolanda D Mahnke; Ruslan D Novosiadly; Senthamil R Selvan; Tasha Sims; Yingdong Zhao; Holden T Maecker
Journal:  J Immunother Cancer       Date:  2020-12       Impact factor: 13.751

Review 2.  Navigating CAR-T cells through the solid-tumour microenvironment.

Authors:  Andrew J Hou; Laurence C Chen; Yvonne Y Chen
Journal:  Nat Rev Drug Discov       Date:  2021-05-10       Impact factor: 84.694

3.  Memory-like HCV-specific CD8+ T cells retain a molecular scar after cure of chronic HCV infection.

Authors:  Nina Hensel; Zuguang Gu; Dominik Wieland; Katharina Jechow; Janine Kemming; Sian Llewellyn-Lacey; Emma Gostick; Oezlem Sogukpinar; Florian Emmerich; David A Price; Bertram Bengsch; Tobias Boettler; Christoph Neumann-Haefelin; Roland Eils; Christian Conrad; Ralf Bartenschlager; Dominic Grün; Naveed Ishaque; Robert Thimme; Maike Hofmann
Journal:  Nat Immunol       Date:  2021-01-04       Impact factor: 25.606

4.  T cell stemness and dysfunction in tumors are triggered by a common mechanism.

Authors:  Suman Kumar Vodnala; Robert Eil; Rigel J Kishton; Madhusudhanan Sukumar; Tori N Yamamoto; Ngoc-Han Ha; Ping-Hsien Lee; MinHwa Shin; Shashank J Patel; Zhiya Yu; Douglas C Palmer; Michael J Kruhlak; Xiaojing Liu; Jason W Locasale; Jing Huang; Rahul Roychoudhuri; Toren Finkel; Christopher A Klebanoff; Nicholas P Restifo
Journal:  Science       Date:  2019-03-29       Impact factor: 47.728

5.  IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors.

Authors:  Lauren Giuffrida; Kevin Sek; Melissa A Henderson; Imran G House; Junyun Lai; Amanda X Y Chen; Kirsten L Todd; Emma V Petley; Sherly Mardiana; Izabela Todorovski; Emily Gruber; Madison J Kelly; Benjamin J Solomon; Stephin J Vervoort; Ricky W Johnstone; Ian A Parish; Paul J Neeson; Lev M Kats; Phillip K Darcy; Paul A Beavis
Journal:  Mol Ther       Date:  2020-07-21       Impact factor: 11.454

Review 6.  Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities.

Authors:  Kristen E Pauken; Michael Dougan; Noel R Rose; Andrew H Lichtman; Arlene H Sharpe
Journal:  Trends Immunol       Date:  2019-04-30       Impact factor: 16.687

7.  Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses.

Authors:  Fan Huang; Christophe Gonçalves; Margarita Bartish; Joelle Rémy-Sarrazin; Mark E Issa; Brendan Cordeiro; Qianyu Guo; Audrey Emond; Mikhael Attias; William Yang; Dany Plourde; Jie Su; Marina Godoy Gimeno; Yao Zhan; Alba Galán; Tomasz Rzymski; Milena Mazan; Magdalena Masiejczyk; Jacek Faber; Elie Khoury; Alexandre Benoit; Natascha Gagnon; David Dankort; Fabrice Journe; Ghanem E Ghanem; Connie M Krawczyk; H Uri Saragovi; Ciriaco A Piccirillo; Nahum Sonenberg; Ivan Topisirovic; Christopher E Rudd; Wilson H Miller; Sonia V Del Rincón
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

8.  Early precursor T cells establish and propagate T cell exhaustion in chronic infection.

Authors:  Daniel T Utzschneider; Sarah S Gabriel; David Chisanga; Renee Gloury; Patrick M Gubser; Ajithkumar Vasanthakumar; Wei Shi; Axel Kallies
Journal:  Nat Immunol       Date:  2020-08-24       Impact factor: 25.606

9.  T Cell Receptor Diversity and Lineage Relationship between Virus-Specific CD8 T Cell Subsets during Chronic Lymphocytic Choriomeningitis Virus Infection.

Authors:  Yun Min Chang; Andreas Wieland; Zheng-Rong Li; Se Jin Im; Donald J McGuire; Haydn T Kissick; Rustom Antia; Rafi Ahmed
Journal:  J Virol       Date:  2020-09-29       Impact factor: 5.103

Review 10.  Cell and tissue engineering in lymph nodes for cancer immunotherapy.

Authors:  Alexander J Najibi; David J Mooney
Journal:  Adv Drug Deliv Rev       Date:  2020-08-01       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.